ClinicalTrials.gg
RecruitingNCT07337408Updated Sep 23, 2026

Characterization of Weaning Practices in ICUs of Global South Countries

An observational study in Weaning From Mechanical Ventilation, Weaning Failure and Weaning From Mechanical Ventilation, Extubation, sponsored by Hospital do Coracao. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Hospital do Coracao · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective observational study to be conducted in intensive care units of Global South countries. Patients on mechanical ventilation for more than 12 hours who have initiated the weaning process and for whom the attending team plans extubation within the next 6 hours will be included. Data will be collected for each patient during the first 7 days after extubation, with follow-up until hospital discharge or death. We plan to conduct the study in intensive care units from Global South countries (low- and middle-income countries predominantly located in the Southern Hemisphere, though some in the Northern Hemisphere are also considered).

02

Conditions studied

  • Weaning From Mechanical Ventilation
  • Weaning Failure
  • Weaning From Mechanical Ventilation, Extubation

Keywords

  • Weaning from mechanical ventilation
  • Weaning Failure
  • Weaning from mechanical ventilation, extubation
03

In context

Lead sponsor

Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients receiving mechanical ventilation for more than 12 hours who are planning to undergo the first separation attempt from the invasive mechanical ventilation (as defined in the WIND Classification) in the next 6 hours or that has undergone a separation attempt less than 2 hours ago will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years.
  • Receiving care at an intensive care unit.
  • Endotracheal intubation.
  • Mechanical ventilation for 12 hours or more.
  • First separation attempt, as defined in the WIND Classification - "Separation attempt from mechanical ventilation: an spontaneous breathing trial with or without extubation, or an extubation directly performed without identified spontaneous breathing trial (whatever the type: planned or unplanned extubation)" - planned to occur in the next 6 hours or that occurred less than 2 hours ago.

Exclusion criteria

Exclusion Criteria:

  • Patients with prior extubation failure.
  • Patients with prior spontaneous breathing trial failure.
  • Patients unable to obey commands.
  • Neuromuscular disease or cervical spinal cord injury.
  • Tracheostomy.
  • Do-not-resuscitate order or for reintubation.
  • Lack of .
  • Terminal extubation.
  • Previously included in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Extubation failure within 7 days.

    Defined as reintubation or death within 7 days after extubation.

    Time frame: 7 days.

Secondary outcomes

  1. Extubation within 28 days.

    Defined as extubation within 28 days after first separation attempt.

    Time frame: 28 days.

  2. Intensive care unit length of stay.

    Defined as the number of days from the time of first separation attempt until discharge from the intensive care unit.

    Time frame: At intensive care unit discharge, up to 28 days.

  3. Hospital length of stay.

    Defined as the number of days from the time of first separation attempt until discharge from the hospital.

    Time frame: At hospital discharge, up to 28 days.

  4. Reintubation or death within 28 days.

    Defined as composite criterion of reintubation or death within 28 days after first separation attempt.

    Time frame: 28 days.

  5. Intensive care unit mortality.

    Defined as mortality from the time of first separation attempt until discharge from the intensive care unit.

    Time frame: At intensive care unit discharge, up to 28 days.

  6. Hospital mortality.

    Defined as mortality from the time of first separation attempt until discharge from the hospital.

    Time frame: At hospital discharge, up to 28 days.

  7. Number of spontaneous breathing trials.

    Defined as the number of spontaneous breathing trials performed after first separation attempt.

    Time frame: 28 days.

  8. WIND classification.

    Group 1 (short weaning): the first separation attempt resulted in a termination of the weaning process within 24 hours (successful separation or early death). • Group 2 (difficult weaning): weaning was terminated after more than 1 day but in less than 1 week after the first separation attempt (successful separation or death). • Group 3 (prolonged weaning): weaning was still not terminated 7 days after the first separation attempt (by success or death).

    Time frame: 28 days.

07

Study locations

1 of 1 sites recruiting
  • Centro Hospitalar Unimed Joinville
    Joinville, Santa Catarina, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 13, 2026
StartActual
May 25, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07337408
Lead sponsor
Hospital do Coracao
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
May 25, 2026
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Aline B Pereira
Contact
linibp@hotmail.com
+55 (47) 99181-8400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion